Economic and Epidemiological Burden of Type 1 Diabetes In France
Author(s)
Nicolas Molinari, PhD1, Marc Nicolino, PhD2, Jacques Beltrand, PhD3, Sandrine Lablanche, PhD4, Clémentine Vabre, PharmD5, Noemie Allali, PharmD6, Nicolas Pages, PharmD5, Amandine Créquer-Grandhomme, PhD6, Amar Bahloul, MD6, Aurélie Schmidt, MSc5, Anne-Lise VATAIRE, PhD6, Anne Vambergue, PhD7.
1CHU Montpellier, Montpellier, France, 2HCL, Bron, France, 3Hôpital Necker, Paris, France, 4CHU Grenoble, Grenoble, France, 5Heva, Lyon, France, 6Sanofi, Gentilly, France, 7CHU Lille, Lille, France.
1CHU Montpellier, Montpellier, France, 2HCL, Bron, France, 3Hôpital Necker, Paris, France, 4CHU Grenoble, Grenoble, France, 5Heva, Lyon, France, 6Sanofi, Gentilly, France, 7CHU Lille, Lille, France.
OBJECTIVES: In 2021, an estimated 8.4 million people worldwide were living with type 1 diabetes (T1D), with 18% of them under the age of 20. In France, T1D accounts for 10% of all diabetes cases and is linked to significant clinical, humanistic, and economic burdens. The HEROES-1 study aimed to assess the epidemiological and economic burden of T1D in France.
METHODS: A retrospective observational study was carried out using data from the SNDS (National Health Data System). T1D patients treated with insulin between 2018 and 2022 were identified using a combination of criteria (Long-Term Disease [LTD], hospitalization, treatments, and a cutoff age of 35 years for incident patients). Patients identified with T2D, iatrogenic, neonatal, gestational or secondary diabetes were excluded. Using five years of retrospective and prospective data through the end of 2023, the database captured patient demographics, clinical characteristics along with diabetes duration and complications, hospitalizations, healthcare utilization, and associated costs.
RESULTS: Between 2018 and 2022, the annual standardized prevalence rate of T1D per 100,000 person-years increased from 200.25 to 231.13, reflecting a 15.4% rise. During the same period, the annual standardized incidence rate grew from 14.70 to 18.31, marking a 24.6% increase. In 2022, the average age of individuals living with T1D was 44.4 years, with men accounting for 56.1%. In 2022 the mean cost per patient was 10,139€, with main cost drivers being drugs, medical devices and hospitalizations. Among incident patient, the average cost per patient was significantly high, reaching €11,112 in the year of T1D diagnosis, compared to an average of €600 per year in the preceding years.
CONCLUSIONS: The HEROES-1 study is among the first to provide longitudinal data on T1D in France over a 10-year period. It delivers up-to-date insights on the burden of T1D, and epidemiological insights aligned with national data published by Santé Publique France.
METHODS: A retrospective observational study was carried out using data from the SNDS (National Health Data System). T1D patients treated with insulin between 2018 and 2022 were identified using a combination of criteria (Long-Term Disease [LTD], hospitalization, treatments, and a cutoff age of 35 years for incident patients). Patients identified with T2D, iatrogenic, neonatal, gestational or secondary diabetes were excluded. Using five years of retrospective and prospective data through the end of 2023, the database captured patient demographics, clinical characteristics along with diabetes duration and complications, hospitalizations, healthcare utilization, and associated costs.
RESULTS: Between 2018 and 2022, the annual standardized prevalence rate of T1D per 100,000 person-years increased from 200.25 to 231.13, reflecting a 15.4% rise. During the same period, the annual standardized incidence rate grew from 14.70 to 18.31, marking a 24.6% increase. In 2022, the average age of individuals living with T1D was 44.4 years, with men accounting for 56.1%. In 2022 the mean cost per patient was 10,139€, with main cost drivers being drugs, medical devices and hospitalizations. Among incident patient, the average cost per patient was significantly high, reaching €11,112 in the year of T1D diagnosis, compared to an average of €600 per year in the preceding years.
CONCLUSIONS: The HEROES-1 study is among the first to provide longitudinal data on T1D in France over a 10-year period. It delivers up-to-date insights on the burden of T1D, and epidemiological insights aligned with national data published by Santé Publique France.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH67
Topic
Economic Evaluation, Epidemiology & Public Health
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)